Clinical Trials
3 trialsNCT00586651 2015-10-08
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00668421 2014-11-26
CEP-701 (Lestaurtinib) in Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT00494585 2012-06-25
CEP-701 for PH-negative Myelofibrosis
M.D. Anderson Cancer Center
Phase 2 Completed